SlideShare ist ein Scribd-Unternehmen logo
1 von 42
Downloaden Sie, um offline zu lesen
Enoxaparin
Proven Across
the Acute Coronary Syndrome
Spectrum
Learning from current guidelines
Dr. Irwan, SpJP-FIHA
Department of Cardiology and Vascular Medicine
Faculty of Medicine, Riau University
Arifin Achmad Hospital - Pekanbaru
IX VII
X
II
Intrinsic pathway
(surface contact)
XII XIIa
XI
Tissue factor
IIa
Xa
XIa
IXa VIIa
VIII VIIIa
Extrinsic pathway
(tissue damage)
Xa
V Va
Fibrinogen Fibrin
Heparins and
LMWH2
Vitamin K antagonists3
Direct thrombin inhibitors4
Factor Xa inhibitors5
(Thrombin)IIa
Targets for AnticoagulantsTargets for Anticoagulants
1Adapted with permission from
Petitou M, et al. Nature. 1991;350(suppl):30-33.
2Hirsh J, et al. Chest. 2001;119(suppl):64S-94S.
3Hirsh J, Fuster V. Circulation. 1994;89:1449-1468.
4Weitz JI, Hirsh J. Chest. 2001;119(suppl):95S-107S.
5Herbert JM, et al. Cardiovasc Drug Rev. 1997;15:1.
Enoxaparin in ACS
Conservative UA/NSTEMI
High risk UA/STEMI
High risk UA/NSTEMI + early invasive
(PCI)
Conservative STEMI
STEMI + Elective PCI
STEMI + Primary PCI
ENOXAPARIN in
conservative ACS
In the TIMI 11B and ESSENCE trials,
meta-analysis showed :
• the primary composite outcome was
significantly lower in patients treated
with enoxaparin compared with UFH
after 1 year of follow-up.
• no significant differences in the rates
of major hemorrhage between
enoxaparin and UFH in either trial or
in the pooled data.
• there was an increased rate of minor
hemorrhage with enoxaparin.
INTERACT:
• Among patients treated with eptifibatide in the setting of
high risk non-ST elevation ACS, administration of
enoxaparin is associated with improves outcomes
compared to currently recommended therapy (UF Heparin)
based on better safety and efficacy
A to Z
• In patients with high-risk NSTE-ACS treated with
AGGRASTAT®† (tirofiban, MSD) and ASA, enoxaparin is an
effective noninferior alternative
to UFH
• Overall rates of bleeding, transfusion, and
thrombocytopenia were low in both heparin groups given
AGGRASTAT and ASA
Slide 8
Adapted from Blazing MA et al JAMA 2004;292(1):55–64.
†Registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
Enoxaparin in high risk ACS
ENOXAPARIN in
high risk + early invasive ACS
SYNERGY
• Efficacy — not superior but at least as
effective as UFH in the overall population (met
criteria for non inferiority)
• Minor bleeding — more frequent with
enoxaparin
• An overview of all recent RCTs comparing
enoxaparin and UFH shows a consistent effect
across the management spectrum
Study N Death or MI at 30 days Major bleeds
ESSENCE ’97 3,171
TIMI 11B ’99 3,910
ACUTE II ’02 525
INTERACT ’03 746
A TO Z ’04 3,620
SYNERGY ’04 9,974
ALL 21,946
0 2010
Incidence (%)
10.1 vs. 11.0
0.5 21
OR (95% CI)
0.91 (0.83 – 0.99)
0 105
Incidence (%)
3.9 vs 3.7
0.1 101
OR (95% CI)
1.1 (0.96 – 1.3)
0.5 21 10102 ∞ 102 10 1
NNT (95% CI)
113 (61 – 1,438)
Enox
+
UFH
+
Enox
+
UFH
+
Enox
+
UFH
+
Randomized Trial
Totality of clinical evidence for
Enoxaparin should lead to level A
Bassand JP, et al. Eur Heart J. 28:1598-1660.
ESC and ACC/AHA NSTE MI ACS GuidelinesESC and ACC/AHA NSTE MI ACS Guidelines
UFHUFH
EnoxaparinEnoxaparin
ENOXAPARIN in STEMI
ASSENT-3
• “In view of the present data and the ease of
administration, enoxaparin might be considered an
attractive alternative anticoagulant treatment when
given in combination with tenecteplase”.
EXTRACT-TIMI 25
● Among STEMI patients undergoing PCI following fibrinolysis,
ENOX was superior to UFH for efficacy with similar safety
- significantly less death or re MI
- both delayed onset and lower incidence of PCI
- no difference in bleeding
- less stroke
On behalf of, A. Shui, A.J. Jacob, N. Gotcheva, L.
Polonetsky, E.M. Antman, E. Braunwald, and the
ExTRACT-TIMI 25 Investigators. EHJ in press
Enoxaparin vs UFH with Fibrinolysis
for STEMI in Pts ≥ 75 years
compared with < 75 years
STEMI < 6 h
Lytic eligible
Lytic choice by MD
(TNK, tPA, rPA, SK)
ENOX
< 75 y: 30 mg IV bolus
SC 1.0 mg / kg q 12 h (Hosp DC)
≥ 75 y: No bolus
SC 0.75 mg / kg q 12 h (Hosp DC)
CrCl < 30: 1.0 mg / kg q 24 h
Double-blind, double-dummy
ASA
Day 30
1°°°° Efficacy Endpoint: Death or Nonfatal MI
1°°°° Safety Endpoint: TIMI Major Hemorrhage
Protocol Design
UFH
60 U / kg bolus (4000 U)
Inf 12 U / kg / h (1000 U / h)
Duration: at least 48 h
Cont’’’’d at MD discretion
Main Results
Primary Endpoint:
Death or non-fatal re-MI by 30 days
Main Secondary Endpoint:
Death, non-fatal re-MI, urgent
revascularization by 30 days
12.0
9.9
UFH UFH
ENOX ENOX
14.5
11.7
Days Days
%% RR = 0.83
p = 0.000003
RR = 0.81
p = 0.000001
N Engl J Med 2006;354:1477-88.
33% RRR in reMI by 48 h (P=0.002)
19% RRR in Death/MI by 72 h (P<0.001)
12% RRR in by 48 h (P=0.02)
Pharmacokinetics
Age <75 years
(N=60)
Age ≥75 years
(N=13)
P-value
AntiXa clearance (L/hr) 0.794 0.654 0.049
Area under curve 0-12hr IU x h/L 9839 4532 <0.001
Area under curve at steady state IU x h/L 10,000 8197 0.005
Day 30 UFH ENOX RRR ARD NNT
Effects of enoxaparin vs
unfractionated heparin
Stratified by age
TIMI major bleeding
Stratified by age
1.1
1.9
3.3
2.9
0
1
2
3
4
5
< 75 years
n = 17,814
≥ 75 years
n = 2513
%Events
Unfractionated heparin Enoxaparin
ARD 0.8%
RR 1.67 (1.31-2.13)
p=<0.0001
ARD 0.4%
RR 1.15 (0.74-1.78)
p=0.53
ExTRACT TIMI 25
• The Enox strategy as implemented in
ExTRACT-TIMI 25 is preferred to the
standard UFH strategy in both younger and
older patients treated with fibrinolysis.
Slide 19
Enoxaparin in the Cath. Lab. Replacing UFH
Is there enough evidence based trial ?
ATOLL
An international randomized study
comparing IV enoxaparin to IV UFH in primary PCI
G. Montalescot, M. Cohen, P. Goldstein,
K. Huber, C. Pollack, U. Zeymer, E. Vicaut
for the ATOLL investigators
G. MONTALESCOT, DISCLOSURE: Research Grants (to the Institution) from Abbott Vascular, Bristol Myers
Squibb, Boston Scientific, Centocor, Cordis, Eli-Lilly, Fédération Française de Cardiologie, Fondation de France,
Guerbet Medical, INSERM, Medtronic, Pfizer, Sanofi-Aventis Group, Société Française de Cardiologie;
Consulting or Lecture Fees from Accumetrics, Astra-Zeneca, Bayer, Biotronik, Boehringer-Ingelheim, Bristol-
Myers Squibb, Daichi-Sankyo, Eisai, Eli-Lilly, Menarini, MSD, Novartis, Portola, Sanofi-Aventis Group, Schering-
Plough , Servier and The Medicines Company.
ATOLL: Acute STEMI Treated with primary PCI and intravenous enoxaparin Or UFH to
Lower ischemic and bleeding events at short- and Long-term follow-up
(Investigator-driven study)
ESC,Stockholm-August30,2010–Hotlinesession
Intravenous 0.5mg/kg Enoxaparin
Time (hours)
Anti-XaIU/mL
0 2 4 6 8 10 12 14 16 18 20
0
0.4
0.8
1.2
0.5 mg/kg IV
1 mg/kg SC
•Choussat et al (elective PCI)
•Miller et al (ACS-PCI)
•Carnendran et al (elective PCI)
•STEEPLE (elective PCI)
•PROTECT –TIMI30 (ACS-PCI)
•Silvain et al (elective PCI)
•FINESSE (primary PCI)
•Brieger et al. (Primary PCI)
PD experience Clinical experience
Choussat et al. JACC. 2002;40:1943-50.
Miller L. J Invasive Cardiol. 2002;14:247-50
Carnendran et al. J Invasive Cardiol. 2003;15:235-8.
Montalescot et al. N Engl J Med. 2006;355:1006-17.
Gibson et al. JACC. 2006;47:2364-2373
Silvain et al. JACC. 2010;55:617-25
Montalescot et al. JACC Cardiovasc Interv. 2010;3:203-12
Brieger et al. Catheter Cardiovasc Interv. 2010 [in press]Sanchez-Pena P. Br J Clin Pharmacol. 2005;60:364-73.
Intravenous enoxaparin vs. UFH in PCI
57%
Major Bleeding
(p=0.004)
23%
Death or re-MI
(p<0.001)
Montalescot G et al. N Engl J Med 2006;355:1006 –17
Gibson MC et al. J Am Coll Cardiol 2007;49:2238–46
?
ATOLL Trial design
STEMI Primary PCI
1°°°° EP: Death, Complication of MI, Procedure Failure, Major Bleeding
Main 2°°°° EP: Death, recurrent MI / ACS, Urgent Revascularization
30 days
Randomization as early as possible (MICU +++)
Real life population (shock, cardiac arrest included)
No anticoagulation and no lytic before Rx
Similar antiplatelet therapy in both groups
ENOXAPARIN IV
0.5 mg/kg
with or without GPIIbIIIa
UFH IV
50-70 IU with GP IIbIIIa
70-100IU without GP IIbIIIa
(Dose ACT-adjusted)
IVRS
Primary PCI
ENOXAPARIN SC UFH IV or SC
Primary Endpoint
Death, Complication of MI, Procedure Failure or Major Bleeding
All Safety Endpoints
Death, Complication of MI or Major bleeding
Net clinical benefit
Conclusions
• This multinational randomized study,
includes 910 patients recruited over 2 years,
that shows a 17% RRR close to significance
(P= 0.07) on an innovative efficacy/safety
composite primary endpoint and was
significant on all the major secondary
standard endpoints used in ACS such as
the triple endpoint (Death, MI,
Revascularization)
• Lovenox® confirming it as a better
alternative to UFH in all ACS settings.
Enoxaparin benefit vs UFH
IV enoxaparin 0.5 mg/kg for PCI
• 1 shot ± GP IIb/IIIa inhibitors
• no ACT monitoring
• stable anticoagulation for 2 hours
(duration of PCI)
29
What are the Guidelines telling us
for UA, NSTEMI & STEMI ?
ESC
&
ACCF / AHA
ACCF / AHA guidelines 2011
(UA / NSTEMI)
2011 ACC/AHA Recommendation
on the Use of Antithrombotics in UA/NSTEMI
ESC guidelines 2012
(AMI - STEMI)
33
Recommendations Class Level
An injectable anticoagulant must be used in primary PCI. I C
Enoxaparin (with or without routine GP IIb/IIIa blocker) may be preferred over UFH. IIb B
Fondaparinux is not recommended for primary PCI. III B
The use of fibrinolysis before planned primary PCI is not recommended. III A
Recommendations Class Level
The anticoagulant can be :
* Enoxaparin i.v. followed by s.c. (using the regimen described below) (preferred over UFH). I A
* UFH given as a weight-adjusted i.v. bolus & infusion. I C
In patients treated with streptokinase, fondaparinux i.v. bolus followed by s.c. dose 24 h later. IIa B
Antithrombin co-therapy with fibrinolysis
Tabel 12 :
Periprocedural antithrombotic medication in primary PCI
Anticoagulants
UFH with or without routine GP IIb/IIIa blocker must be used in patients not receiving bivalirudin or
enoxaparin.
I C
Tabel 13 :
Fibrinolytic therapy
Bivalirudin (with use of GP IIb/IIIa blocker restricted to bailout) is recommended over UHF & GP IIb/IIIa
blocker.
I A
Anticoagulation is recommended in STEMI patients treated with lytics until revascularization (if
performed) or for the duration of hospital stay up to 8 days. I C
ESC guidelines 2012
(AMI - STEMI)
34
Enoxaparin 0.5 mg/kg i.v. bolus.
In patients <75 years of age :
In patients >75 years of age :
In patients with creatinine clearance of <30 mL/min, regardles of age :
the s.c. doses are given once every 24 h.
Enoxaparin Same dose as with fibrinolytic therapy.
With primary PCI
Tabel 16 :
Doses of antiplatelet & antithrombin co-therapies
Doses of antithrombin co-therapies
Enoxaparin
No adjusment of bolus dose. Following thrombolysis, in patients with creatinin
clearance <30 mL/min, the s.c. doses are given once every 24 h.
Enoxaparin
With fibrinolytic therapy
Tabel 18 :
Recommendation
30 mg i.v. bolus followed 15 min later by 1 mg/kg s.c. every 12 h until hospital discharge
for a maximum of 8 days. The first two doses should not exceed 100 mg.
no i.v. bolus; start with s.c. dose of 0.75 mg/kg with a maximum of 75 mg for the first
two s.c. doses.
Initial dosing of antithrombotic agents in patients with chronic kidney disease
(estimated creatinine clearance <60 mL/min)
Without reperfusion therapy
ACCF / AHA guidelines 2013
(STEMI)
ACCF/AHA/SCAI Guideline
on PCI and CABG
2011 update
Key points
- Loading dose for all P2Y12 inhibitors is recommended (Class I-A)
- 600 mg loading recommended for clopidogrel
- Limitations imposed on prasugrel
- Issue of compliance posed against ticagrelor
Key points
Enoxaparin
-An additional dose of 0.3 mg/kg IV enoxaparin should be
administered at the time of PCI to patients who have received fewer
than 2 therapeutic subcutaneous doses (eg, 1 mg/kg) or received the
last subcutaneous enoxaparin dose 8 to 12 hours before PCI. (Class
I-B)
-Performance of PCI with enoxaparin may be reasonable in patients
either treated with ““““upstream”””” subcutaneous enoxaparin for
UA/NSTEMI or who have not received prior antithrombin therapy and
are administered IV enoxaparin at the time of PCI. (Class IIb-B)
-UFH should not be given to patients already receiving therapeutic
subcutaneous enoxaparin. (Class III-B: HARM)
Fondaparinux
-Fondaparinux should not be used as the sole anticoagulant to
support PCI. An additional anticoagulant with anti-IIa activity should
be administered because of the risk of catheter thrombosis. (Class
III-C: HARM)
Enoxaparin Proven Across
the ACS Spectrum
Conservative UA/NSTEMI
* TESMA 1997
High risk UA/STEMI
* A TO Z 2004
High risk UA/NSTEMI + early invasive (PCI)
* SYNERGY 2004
Conservative STEMI
* EXTRACT TIMI25 2005
STEMI + Elective PCI
* STEEPLE 2006
STEMI + Primary PCI
* ATOLL 2010
THANK YOUTHANK YOUTHANK YOUTHANK YOU

Weitere ähnliche Inhalte

Was ist angesagt?

Role of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsRole of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsPraveen Nagula
 
Novel oral anticoagulants in CKD review, Moh'd sharshir
Novel oral anticoagulants in CKD review, Moh'd sharshirNovel oral anticoagulants in CKD review, Moh'd sharshir
Novel oral anticoagulants in CKD review, Moh'd sharshirMoh'd sharshir
 
Paraglide HF Trial.pptx
Paraglide HF Trial.pptxParaglide HF Trial.pptx
Paraglide HF Trial.pptxssuser2b7a9d
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailurePraveen Nagula
 
Isicam, high bleeding risk pci,2016,isman
Isicam, high bleeding risk pci,2016,ismanIsicam, high bleeding risk pci,2016,isman
Isicam, high bleeding risk pci,2016,ismanIsman Firdaus
 
Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome Paiboon Chotnoparatpat
 
Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat MNDU net
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...SYEDRAZA56411
 
Iron Deficiency : An Overlooked Aspect of Heart Failure Management
Iron Deficiency : An Overlooked Aspect of Heart Failure ManagementIron Deficiency : An Overlooked Aspect of Heart Failure Management
Iron Deficiency : An Overlooked Aspect of Heart Failure Managementmagdy elmasry
 
Ticagrelor in acute myocardial infarction
Ticagrelor in acute myocardial infarctionTicagrelor in acute myocardial infarction
Ticagrelor in acute myocardial infarctionVasif Mayan
 
NOAC Reversal Agents
NOAC Reversal AgentsNOAC Reversal Agents
NOAC Reversal AgentsAlexander Mok
 

Was ist angesagt? (20)

Role of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic eventsRole of statin and clopidogrel in atherothrombotic events
Role of statin and clopidogrel in atherothrombotic events
 
DAPA-HF Trial
DAPA-HF TrialDAPA-HF Trial
DAPA-HF Trial
 
Pioneer hf
Pioneer   hfPioneer   hf
Pioneer hf
 
Monotherapy with Potent P2Y12 Inhibitors - Dr. de la Torre
Monotherapy with Potent P2Y12 Inhibitors - Dr. de la TorreMonotherapy with Potent P2Y12 Inhibitors - Dr. de la Torre
Monotherapy with Potent P2Y12 Inhibitors - Dr. de la Torre
 
Novel oral anticoagulants in CKD review, Moh'd sharshir
Novel oral anticoagulants in CKD review, Moh'd sharshirNovel oral anticoagulants in CKD review, Moh'd sharshir
Novel oral anticoagulants in CKD review, Moh'd sharshir
 
Paraglide HF Trial.pptx
Paraglide HF Trial.pptxParaglide HF Trial.pptx
Paraglide HF Trial.pptx
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
Hypertension
HypertensionHypertension
Hypertension
 
Erythropoetin - From Bench to Bedside
Erythropoetin - From Bench to Bedside Erythropoetin - From Bench to Bedside
Erythropoetin - From Bench to Bedside
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart Failure
 
Telmisartan combination uses
Telmisartan combination usesTelmisartan combination uses
Telmisartan combination uses
 
Isicam, high bleeding risk pci,2016,isman
Isicam, high bleeding risk pci,2016,ismanIsicam, high bleeding risk pci,2016,isman
Isicam, high bleeding risk pci,2016,isman
 
Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome
 
Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat
 
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada SelimSGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
 
Premixed insulin dosing in actual practice
Premixed insulin dosing in actual practicePremixed insulin dosing in actual practice
Premixed insulin dosing in actual practice
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
 
Iron Deficiency : An Overlooked Aspect of Heart Failure Management
Iron Deficiency : An Overlooked Aspect of Heart Failure ManagementIron Deficiency : An Overlooked Aspect of Heart Failure Management
Iron Deficiency : An Overlooked Aspect of Heart Failure Management
 
Ticagrelor in acute myocardial infarction
Ticagrelor in acute myocardial infarctionTicagrelor in acute myocardial infarction
Ticagrelor in acute myocardial infarction
 
NOAC Reversal Agents
NOAC Reversal AgentsNOAC Reversal Agents
NOAC Reversal Agents
 

Andere mochten auch

Emergency Medical System Network for STEMI Management
Emergency Medical System Network for STEMI ManagementEmergency Medical System Network for STEMI Management
Emergency Medical System Network for STEMI ManagementPERKI Pekanbaru
 
Patophysiology of ACS: Role of Thrombosis
Patophysiology of ACS: Role of ThrombosisPatophysiology of ACS: Role of Thrombosis
Patophysiology of ACS: Role of ThrombosisPERKI Pekanbaru
 
Role of Statin in Secondary Prevention of ACS
Role of Statin in Secondary Prevention of ACSRole of Statin in Secondary Prevention of ACS
Role of Statin in Secondary Prevention of ACSPERKI Pekanbaru
 
New Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentNew Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentPERKI Pekanbaru
 
Angina Management with Metabolic Agents
Angina Management with Metabolic AgentsAngina Management with Metabolic Agents
Angina Management with Metabolic AgentsPERKI Pekanbaru
 
Secondary Prevention after ACS - Role of Beta Blockers
Secondary Prevention after ACS - Role of Beta BlockersSecondary Prevention after ACS - Role of Beta Blockers
Secondary Prevention after ACS - Role of Beta BlockersPERKI Pekanbaru
 
Haemodynamic Instability in STEMI
Haemodynamic Instability in STEMIHaemodynamic Instability in STEMI
Haemodynamic Instability in STEMIPERKI Pekanbaru
 
Secondary Prevention after ACS: Focused on Anticoagulant Therapy
Secondary Prevention after ACS: Focused on Anticoagulant TherapySecondary Prevention after ACS: Focused on Anticoagulant Therapy
Secondary Prevention after ACS: Focused on Anticoagulant TherapyPERKI Pekanbaru
 
Electrical Instability in ACS
Electrical Instability in ACSElectrical Instability in ACS
Electrical Instability in ACSPERKI Pekanbaru
 
Recent Updated Pathogenesis and Management of Heart Failure:
Recent Updated Pathogenesis and Management of Heart Failure:Recent Updated Pathogenesis and Management of Heart Failure:
Recent Updated Pathogenesis and Management of Heart Failure:PERKI Pekanbaru
 
Role of Inflammation in Patophysiology of ACS
Role of Inflammation in Patophysiology of ACSRole of Inflammation in Patophysiology of ACS
Role of Inflammation in Patophysiology of ACSPERKI Pekanbaru
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsPERKI Pekanbaru
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementPERKI Pekanbaru
 
Cardiac Biomarkers in ACS
Cardiac Biomarkers in ACSCardiac Biomarkers in ACS
Cardiac Biomarkers in ACSPERKI Pekanbaru
 
Role of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACSRole of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACSPERKI Pekanbaru
 
Echocardiography for Acute Coronary Syndrome
Echocardiography for Acute Coronary SyndromeEchocardiography for Acute Coronary Syndrome
Echocardiography for Acute Coronary SyndromePERKI Pekanbaru
 
Global Burden of Coronary Heart Disease
Global Burden of Coronary Heart DiseaseGlobal Burden of Coronary Heart Disease
Global Burden of Coronary Heart DiseasePERKI Pekanbaru
 

Andere mochten auch (20)

Emergency Medical System Network for STEMI Management
Emergency Medical System Network for STEMI ManagementEmergency Medical System Network for STEMI Management
Emergency Medical System Network for STEMI Management
 
Patophysiology of ACS: Role of Thrombosis
Patophysiology of ACS: Role of ThrombosisPatophysiology of ACS: Role of Thrombosis
Patophysiology of ACS: Role of Thrombosis
 
Role of Statin in Secondary Prevention of ACS
Role of Statin in Secondary Prevention of ACSRole of Statin in Secondary Prevention of ACS
Role of Statin in Secondary Prevention of ACS
 
New Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS TreatmentNew Option of Antiplatelet and Controversies in ACS Treatment
New Option of Antiplatelet and Controversies in ACS Treatment
 
Angina Management with Metabolic Agents
Angina Management with Metabolic AgentsAngina Management with Metabolic Agents
Angina Management with Metabolic Agents
 
Secondary Prevention after ACS - Role of Beta Blockers
Secondary Prevention after ACS - Role of Beta BlockersSecondary Prevention after ACS - Role of Beta Blockers
Secondary Prevention after ACS - Role of Beta Blockers
 
Primary PCI
Primary PCIPrimary PCI
Primary PCI
 
Haemodynamic Instability in STEMI
Haemodynamic Instability in STEMIHaemodynamic Instability in STEMI
Haemodynamic Instability in STEMI
 
Secondary Prevention after ACS: Focused on Anticoagulant Therapy
Secondary Prevention after ACS: Focused on Anticoagulant TherapySecondary Prevention after ACS: Focused on Anticoagulant Therapy
Secondary Prevention after ACS: Focused on Anticoagulant Therapy
 
Electrical Instability in ACS
Electrical Instability in ACSElectrical Instability in ACS
Electrical Instability in ACS
 
Recent Updated Pathogenesis and Management of Heart Failure:
Recent Updated Pathogenesis and Management of Heart Failure:Recent Updated Pathogenesis and Management of Heart Failure:
Recent Updated Pathogenesis and Management of Heart Failure:
 
Role of Inflammation in Patophysiology of ACS
Role of Inflammation in Patophysiology of ACSRole of Inflammation in Patophysiology of ACS
Role of Inflammation in Patophysiology of ACS
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS Management
 
Cardiac Biomarkers in ACS
Cardiac Biomarkers in ACSCardiac Biomarkers in ACS
Cardiac Biomarkers in ACS
 
Role of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACSRole of ACE Inhibitors as Secondary Prevention in ACS
Role of ACE Inhibitors as Secondary Prevention in ACS
 
Fibrinolytic Therapy
Fibrinolytic TherapyFibrinolytic Therapy
Fibrinolytic Therapy
 
Echocardiography for Acute Coronary Syndrome
Echocardiography for Acute Coronary SyndromeEchocardiography for Acute Coronary Syndrome
Echocardiography for Acute Coronary Syndrome
 
Global Burden of Coronary Heart Disease
Global Burden of Coronary Heart DiseaseGlobal Burden of Coronary Heart Disease
Global Burden of Coronary Heart Disease
 
Genesis
GenesisGenesis
Genesis
 

Ähnlich wie Enoxaparin Benefits in Acute Coronary Syndrome

Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885MedicineAndHealthNeurolog
 
Fondapa Mon
Fondapa MonFondapa Mon
Fondapa Monhospital
 
Post cardiac arrest care in ED
Post cardiac arrest care in EDPost cardiac arrest care in ED
Post cardiac arrest care in EDkellyam18
 
Perioperative Beta Blockers in non-cardiac surgery and POISE
Perioperative Beta Blockers in non-cardiac surgery and POISEPerioperative Beta Blockers in non-cardiac surgery and POISE
Perioperative Beta Blockers in non-cardiac surgery and POISEMedPeds Hospitalist
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxdrsbansal2000
 
Strive Teleconf Presentation Sept13 2006
Strive Teleconf Presentation Sept13 2006Strive Teleconf Presentation Sept13 2006
Strive Teleconf Presentation Sept13 2006MedicineAndHealthCancer
 
Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Gillian Gordon Perue
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020EkaPratiwi69
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011taem
 
Samama naco mars 2014
Samama naco mars 2014 Samama naco mars 2014
Samama naco mars 2014 kbtrauma
 
Weaning from mechanical ventilation
Weaning from mechanical ventilationWeaning from mechanical ventilation
Weaning from mechanical ventilationSucharita Ray
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxNayyarSaleem2
 
Bruchanski final x
Bruchanski final xBruchanski final x
Bruchanski final xchiefhgh
 

Ähnlich wie Enoxaparin Benefits in Acute Coronary Syndrome (20)

Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885
 
Fondapa Mon
Fondapa MonFondapa Mon
Fondapa Mon
 
Intervencionismo en Cardiopatía Isquémica
Intervencionismo en Cardiopatía IsquémicaIntervencionismo en Cardiopatía Isquémica
Intervencionismo en Cardiopatía Isquémica
 
Post cardiac arrest care in ED
Post cardiac arrest care in EDPost cardiac arrest care in ED
Post cardiac arrest care in ED
 
Perioperative Beta Blockers in non-cardiac surgery and POISE
Perioperative Beta Blockers in non-cardiac surgery and POISEPerioperative Beta Blockers in non-cardiac surgery and POISE
Perioperative Beta Blockers in non-cardiac surgery and POISE
 
NSAIDs and ICON-G
NSAIDs and ICON-GNSAIDs and ICON-G
NSAIDs and ICON-G
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptx
 
Update de los estudios de ABSORB hasta 2014 - Dr. Flavio Ribichini
Update de los estudios de ABSORB hasta 2014 - Dr.  Flavio RibichiniUpdate de los estudios de ABSORB hasta 2014 - Dr.  Flavio Ribichini
Update de los estudios de ABSORB hasta 2014 - Dr. Flavio Ribichini
 
Low Molecular Weight Heparin - Dr. Montalescot
Low Molecular Weight Heparin - Dr. MontalescotLow Molecular Weight Heparin - Dr. Montalescot
Low Molecular Weight Heparin - Dr. Montalescot
 
Strive Teleconf Presentation Sept13 2006
Strive Teleconf Presentation Sept13 2006Strive Teleconf Presentation Sept13 2006
Strive Teleconf Presentation Sept13 2006
 
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
 
Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021
 
Resuscitation update by Professor Peter Morley
Resuscitation update by Professor Peter MorleyResuscitation update by Professor Peter Morley
Resuscitation update by Professor Peter Morley
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011
 
Samama naco mars 2014
Samama naco mars 2014 Samama naco mars 2014
Samama naco mars 2014
 
Weaning from mechanical ventilation
Weaning from mechanical ventilationWeaning from mechanical ventilation
Weaning from mechanical ventilation
 
Primary angioplasty
Primary angioplastyPrimary angioplasty
Primary angioplasty
 
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxEffect Of Remote Ischemic Preconditioning On AKI Among.pptx
Effect Of Remote Ischemic Preconditioning On AKI Among.pptx
 
Bruchanski final x
Bruchanski final xBruchanski final x
Bruchanski final x
 

Kürzlich hochgeladen

💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...Taniya Sharma
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...hotbabesbook
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...narwatsonia7
 
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Mumbai Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...Dipal Arora
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...astropune
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...chandars293
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...aartirawatdelhi
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...chandars293
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...indiancallgirl4rent
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
 
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsBangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsGfnyt
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort ServicePremium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Servicevidya singh
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...vidya singh
 
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 

Kürzlich hochgeladen (20)

💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
 
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Mumbai Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 9907093804 Top Class Call Girl Service Ava...
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
 
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual NeedsBangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
Bangalore Call Girl Whatsapp Number 100% Complete Your Sexual Needs
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
 
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort ServicePremium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
Premium Call Girls Cottonpet Whatsapp 7001035870 Independent Escort Service
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
 
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
 

Enoxaparin Benefits in Acute Coronary Syndrome

  • 1. Enoxaparin Proven Across the Acute Coronary Syndrome Spectrum Learning from current guidelines Dr. Irwan, SpJP-FIHA Department of Cardiology and Vascular Medicine Faculty of Medicine, Riau University Arifin Achmad Hospital - Pekanbaru
  • 2. IX VII X II Intrinsic pathway (surface contact) XII XIIa XI Tissue factor IIa Xa XIa IXa VIIa VIII VIIIa Extrinsic pathway (tissue damage) Xa V Va Fibrinogen Fibrin Heparins and LMWH2 Vitamin K antagonists3 Direct thrombin inhibitors4 Factor Xa inhibitors5 (Thrombin)IIa Targets for AnticoagulantsTargets for Anticoagulants 1Adapted with permission from Petitou M, et al. Nature. 1991;350(suppl):30-33. 2Hirsh J, et al. Chest. 2001;119(suppl):64S-94S. 3Hirsh J, Fuster V. Circulation. 1994;89:1449-1468. 4Weitz JI, Hirsh J. Chest. 2001;119(suppl):95S-107S. 5Herbert JM, et al. Cardiovasc Drug Rev. 1997;15:1.
  • 3.
  • 4.
  • 5. Enoxaparin in ACS Conservative UA/NSTEMI High risk UA/STEMI High risk UA/NSTEMI + early invasive (PCI) Conservative STEMI STEMI + Elective PCI STEMI + Primary PCI
  • 6.
  • 7. ENOXAPARIN in conservative ACS In the TIMI 11B and ESSENCE trials, meta-analysis showed : • the primary composite outcome was significantly lower in patients treated with enoxaparin compared with UFH after 1 year of follow-up. • no significant differences in the rates of major hemorrhage between enoxaparin and UFH in either trial or in the pooled data. • there was an increased rate of minor hemorrhage with enoxaparin.
  • 8. INTERACT: • Among patients treated with eptifibatide in the setting of high risk non-ST elevation ACS, administration of enoxaparin is associated with improves outcomes compared to currently recommended therapy (UF Heparin) based on better safety and efficacy A to Z • In patients with high-risk NSTE-ACS treated with AGGRASTAT®† (tirofiban, MSD) and ASA, enoxaparin is an effective noninferior alternative to UFH • Overall rates of bleeding, transfusion, and thrombocytopenia were low in both heparin groups given AGGRASTAT and ASA Slide 8 Adapted from Blazing MA et al JAMA 2004;292(1):55–64. †Registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Enoxaparin in high risk ACS
  • 9. ENOXAPARIN in high risk + early invasive ACS SYNERGY • Efficacy — not superior but at least as effective as UFH in the overall population (met criteria for non inferiority) • Minor bleeding — more frequent with enoxaparin • An overview of all recent RCTs comparing enoxaparin and UFH shows a consistent effect across the management spectrum
  • 10. Study N Death or MI at 30 days Major bleeds ESSENCE ’97 3,171 TIMI 11B ’99 3,910 ACUTE II ’02 525 INTERACT ’03 746 A TO Z ’04 3,620 SYNERGY ’04 9,974 ALL 21,946 0 2010 Incidence (%) 10.1 vs. 11.0 0.5 21 OR (95% CI) 0.91 (0.83 – 0.99) 0 105 Incidence (%) 3.9 vs 3.7 0.1 101 OR (95% CI) 1.1 (0.96 – 1.3) 0.5 21 10102 ∞ 102 10 1 NNT (95% CI) 113 (61 – 1,438) Enox + UFH + Enox + UFH + Enox + UFH + Randomized Trial Totality of clinical evidence for Enoxaparin should lead to level A Bassand JP, et al. Eur Heart J. 28:1598-1660. ESC and ACC/AHA NSTE MI ACS GuidelinesESC and ACC/AHA NSTE MI ACS Guidelines UFHUFH EnoxaparinEnoxaparin
  • 11. ENOXAPARIN in STEMI ASSENT-3 • “In view of the present data and the ease of administration, enoxaparin might be considered an attractive alternative anticoagulant treatment when given in combination with tenecteplase”. EXTRACT-TIMI 25 ● Among STEMI patients undergoing PCI following fibrinolysis, ENOX was superior to UFH for efficacy with similar safety - significantly less death or re MI - both delayed onset and lower incidence of PCI - no difference in bleeding - less stroke
  • 12. On behalf of, A. Shui, A.J. Jacob, N. Gotcheva, L. Polonetsky, E.M. Antman, E. Braunwald, and the ExTRACT-TIMI 25 Investigators. EHJ in press Enoxaparin vs UFH with Fibrinolysis for STEMI in Pts ≥ 75 years compared with < 75 years
  • 13. STEMI < 6 h Lytic eligible Lytic choice by MD (TNK, tPA, rPA, SK) ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ≥ 75 y: No bolus SC 0.75 mg / kg q 12 h (Hosp DC) CrCl < 30: 1.0 mg / kg q 24 h Double-blind, double-dummy ASA Day 30 1°°°° Efficacy Endpoint: Death or Nonfatal MI 1°°°° Safety Endpoint: TIMI Major Hemorrhage Protocol Design UFH 60 U / kg bolus (4000 U) Inf 12 U / kg / h (1000 U / h) Duration: at least 48 h Cont’’’’d at MD discretion
  • 14. Main Results Primary Endpoint: Death or non-fatal re-MI by 30 days Main Secondary Endpoint: Death, non-fatal re-MI, urgent revascularization by 30 days 12.0 9.9 UFH UFH ENOX ENOX 14.5 11.7 Days Days %% RR = 0.83 p = 0.000003 RR = 0.81 p = 0.000001 N Engl J Med 2006;354:1477-88. 33% RRR in reMI by 48 h (P=0.002) 19% RRR in Death/MI by 72 h (P<0.001) 12% RRR in by 48 h (P=0.02)
  • 15. Pharmacokinetics Age <75 years (N=60) Age ≥75 years (N=13) P-value AntiXa clearance (L/hr) 0.794 0.654 0.049 Area under curve 0-12hr IU x h/L 9839 4532 <0.001 Area under curve at steady state IU x h/L 10,000 8197 0.005
  • 16. Day 30 UFH ENOX RRR ARD NNT Effects of enoxaparin vs unfractionated heparin Stratified by age
  • 17. TIMI major bleeding Stratified by age 1.1 1.9 3.3 2.9 0 1 2 3 4 5 < 75 years n = 17,814 ≥ 75 years n = 2513 %Events Unfractionated heparin Enoxaparin ARD 0.8% RR 1.67 (1.31-2.13) p=<0.0001 ARD 0.4% RR 1.15 (0.74-1.78) p=0.53
  • 18. ExTRACT TIMI 25 • The Enox strategy as implemented in ExTRACT-TIMI 25 is preferred to the standard UFH strategy in both younger and older patients treated with fibrinolysis.
  • 19. Slide 19 Enoxaparin in the Cath. Lab. Replacing UFH Is there enough evidence based trial ?
  • 20. ATOLL An international randomized study comparing IV enoxaparin to IV UFH in primary PCI G. Montalescot, M. Cohen, P. Goldstein, K. Huber, C. Pollack, U. Zeymer, E. Vicaut for the ATOLL investigators G. MONTALESCOT, DISCLOSURE: Research Grants (to the Institution) from Abbott Vascular, Bristol Myers Squibb, Boston Scientific, Centocor, Cordis, Eli-Lilly, Fédération Française de Cardiologie, Fondation de France, Guerbet Medical, INSERM, Medtronic, Pfizer, Sanofi-Aventis Group, Société Française de Cardiologie; Consulting or Lecture Fees from Accumetrics, Astra-Zeneca, Bayer, Biotronik, Boehringer-Ingelheim, Bristol- Myers Squibb, Daichi-Sankyo, Eisai, Eli-Lilly, Menarini, MSD, Novartis, Portola, Sanofi-Aventis Group, Schering- Plough , Servier and The Medicines Company. ATOLL: Acute STEMI Treated with primary PCI and intravenous enoxaparin Or UFH to Lower ischemic and bleeding events at short- and Long-term follow-up (Investigator-driven study) ESC,Stockholm-August30,2010–Hotlinesession
  • 21. Intravenous 0.5mg/kg Enoxaparin Time (hours) Anti-XaIU/mL 0 2 4 6 8 10 12 14 16 18 20 0 0.4 0.8 1.2 0.5 mg/kg IV 1 mg/kg SC •Choussat et al (elective PCI) •Miller et al (ACS-PCI) •Carnendran et al (elective PCI) •STEEPLE (elective PCI) •PROTECT –TIMI30 (ACS-PCI) •Silvain et al (elective PCI) •FINESSE (primary PCI) •Brieger et al. (Primary PCI) PD experience Clinical experience Choussat et al. JACC. 2002;40:1943-50. Miller L. J Invasive Cardiol. 2002;14:247-50 Carnendran et al. J Invasive Cardiol. 2003;15:235-8. Montalescot et al. N Engl J Med. 2006;355:1006-17. Gibson et al. JACC. 2006;47:2364-2373 Silvain et al. JACC. 2010;55:617-25 Montalescot et al. JACC Cardiovasc Interv. 2010;3:203-12 Brieger et al. Catheter Cardiovasc Interv. 2010 [in press]Sanchez-Pena P. Br J Clin Pharmacol. 2005;60:364-73.
  • 22. Intravenous enoxaparin vs. UFH in PCI 57% Major Bleeding (p=0.004) 23% Death or re-MI (p<0.001) Montalescot G et al. N Engl J Med 2006;355:1006 –17 Gibson MC et al. J Am Coll Cardiol 2007;49:2238–46 ?
  • 23. ATOLL Trial design STEMI Primary PCI 1°°°° EP: Death, Complication of MI, Procedure Failure, Major Bleeding Main 2°°°° EP: Death, recurrent MI / ACS, Urgent Revascularization 30 days Randomization as early as possible (MICU +++) Real life population (shock, cardiac arrest included) No anticoagulation and no lytic before Rx Similar antiplatelet therapy in both groups ENOXAPARIN IV 0.5 mg/kg with or without GPIIbIIIa UFH IV 50-70 IU with GP IIbIIIa 70-100IU without GP IIbIIIa (Dose ACT-adjusted) IVRS Primary PCI ENOXAPARIN SC UFH IV or SC
  • 24. Primary Endpoint Death, Complication of MI, Procedure Failure or Major Bleeding
  • 26. Death, Complication of MI or Major bleeding Net clinical benefit
  • 27. Conclusions • This multinational randomized study, includes 910 patients recruited over 2 years, that shows a 17% RRR close to significance (P= 0.07) on an innovative efficacy/safety composite primary endpoint and was significant on all the major secondary standard endpoints used in ACS such as the triple endpoint (Death, MI, Revascularization) • Lovenox® confirming it as a better alternative to UFH in all ACS settings.
  • 28. Enoxaparin benefit vs UFH IV enoxaparin 0.5 mg/kg for PCI • 1 shot ± GP IIb/IIIa inhibitors • no ACT monitoring • stable anticoagulation for 2 hours (duration of PCI)
  • 29. 29 What are the Guidelines telling us for UA, NSTEMI & STEMI ? ESC & ACCF / AHA
  • 30. ACCF / AHA guidelines 2011 (UA / NSTEMI)
  • 31. 2011 ACC/AHA Recommendation on the Use of Antithrombotics in UA/NSTEMI
  • 32.
  • 33. ESC guidelines 2012 (AMI - STEMI) 33 Recommendations Class Level An injectable anticoagulant must be used in primary PCI. I C Enoxaparin (with or without routine GP IIb/IIIa blocker) may be preferred over UFH. IIb B Fondaparinux is not recommended for primary PCI. III B The use of fibrinolysis before planned primary PCI is not recommended. III A Recommendations Class Level The anticoagulant can be : * Enoxaparin i.v. followed by s.c. (using the regimen described below) (preferred over UFH). I A * UFH given as a weight-adjusted i.v. bolus & infusion. I C In patients treated with streptokinase, fondaparinux i.v. bolus followed by s.c. dose 24 h later. IIa B Antithrombin co-therapy with fibrinolysis Tabel 12 : Periprocedural antithrombotic medication in primary PCI Anticoagulants UFH with or without routine GP IIb/IIIa blocker must be used in patients not receiving bivalirudin or enoxaparin. I C Tabel 13 : Fibrinolytic therapy Bivalirudin (with use of GP IIb/IIIa blocker restricted to bailout) is recommended over UHF & GP IIb/IIIa blocker. I A Anticoagulation is recommended in STEMI patients treated with lytics until revascularization (if performed) or for the duration of hospital stay up to 8 days. I C
  • 34. ESC guidelines 2012 (AMI - STEMI) 34 Enoxaparin 0.5 mg/kg i.v. bolus. In patients <75 years of age : In patients >75 years of age : In patients with creatinine clearance of <30 mL/min, regardles of age : the s.c. doses are given once every 24 h. Enoxaparin Same dose as with fibrinolytic therapy. With primary PCI Tabel 16 : Doses of antiplatelet & antithrombin co-therapies Doses of antithrombin co-therapies Enoxaparin No adjusment of bolus dose. Following thrombolysis, in patients with creatinin clearance <30 mL/min, the s.c. doses are given once every 24 h. Enoxaparin With fibrinolytic therapy Tabel 18 : Recommendation 30 mg i.v. bolus followed 15 min later by 1 mg/kg s.c. every 12 h until hospital discharge for a maximum of 8 days. The first two doses should not exceed 100 mg. no i.v. bolus; start with s.c. dose of 0.75 mg/kg with a maximum of 75 mg for the first two s.c. doses. Initial dosing of antithrombotic agents in patients with chronic kidney disease (estimated creatinine clearance <60 mL/min) Without reperfusion therapy
  • 35. ACCF / AHA guidelines 2013 (STEMI)
  • 36.
  • 37.
  • 38. ACCF/AHA/SCAI Guideline on PCI and CABG 2011 update
  • 39. Key points - Loading dose for all P2Y12 inhibitors is recommended (Class I-A) - 600 mg loading recommended for clopidogrel - Limitations imposed on prasugrel - Issue of compliance posed against ticagrelor
  • 40. Key points Enoxaparin -An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of PCI to patients who have received fewer than 2 therapeutic subcutaneous doses (eg, 1 mg/kg) or received the last subcutaneous enoxaparin dose 8 to 12 hours before PCI. (Class I-B) -Performance of PCI with enoxaparin may be reasonable in patients either treated with ““““upstream”””” subcutaneous enoxaparin for UA/NSTEMI or who have not received prior antithrombin therapy and are administered IV enoxaparin at the time of PCI. (Class IIb-B) -UFH should not be given to patients already receiving therapeutic subcutaneous enoxaparin. (Class III-B: HARM) Fondaparinux -Fondaparinux should not be used as the sole anticoagulant to support PCI. An additional anticoagulant with anti-IIa activity should be administered because of the risk of catheter thrombosis. (Class III-C: HARM)
  • 41. Enoxaparin Proven Across the ACS Spectrum Conservative UA/NSTEMI * TESMA 1997 High risk UA/STEMI * A TO Z 2004 High risk UA/NSTEMI + early invasive (PCI) * SYNERGY 2004 Conservative STEMI * EXTRACT TIMI25 2005 STEMI + Elective PCI * STEEPLE 2006 STEMI + Primary PCI * ATOLL 2010
  • 42. THANK YOUTHANK YOUTHANK YOUTHANK YOU